Elimination of Cervical Cancer: Challenges Promoting the HPV Vaccine in China

Lihui Wei1 · Xing Xie1 · Jihong Liu1 · Youlin Qiao1 · Fanghui Zhao1 · Ting Wu1 · Jun Zhang1 · Ding Ma1 · Beihua Kong1 · Wen Chen1 · Chao Zhao1 · Yun Zhao1 · Jingran Li1 · Mingzhu Li1 · Ningshao Xia1

© Association of Gynecologic Oncologists of India 2021

Abstract

Objective Cervical cancers present major threats to women’s health in China. Eliminating cervical cancer in China is a huge challenge, with application of the HPV vaccine, which is an important part.

Methods There are currently four HPV vaccines available in China: E-coli bv-HPV (Wantai, China), bv-HPV, qv-HPV (GSK, UK), and 9v-HPV (MSD, USA). To observe the immunogenicity, efficacy, and safety of these four vaccines in China, we formed the “Chinese Expert Consensus on the Clinical Application of HPV Vaccine.”

Results At 7 months after vaccination, all vaccinated subjects had the same immunogenic response to either HPV16 or HPV18, ranging from 96 to 100%, and antibody production in girls aged 9–14 years was 2–3 times higher than that in adult women. Efficacy of the four vaccines against CIN2+ ranged from 87.3% to 100%, with prevention of HPV-associated infection reaching 96% ~ 97% at 12 months. Clinical trials showed bv-HPV and qv-HPV vaccine were also safe in women aged 18–45 years. Clinical trials of the 9v-HPV vaccine are underway. HPV vaccination is currently voluntary and self-paid in China. The “Chinese Expert Consensus on the Clinical Application of HPV Vaccine” will work to promote the application of HPV vaccine in China.

Conclusions In clinical studies, the available HPV vaccines showed excellent efficacy, safety, and immunogenicity in Chinese women. We will continue strengthening screening and encouraging HPV vaccination.

Keywords HPV vaccine · Efficacy · Safety · Expert consensus

Introduction

Cervical cancer is the most common malignant tumor in women and poses a significant threat to the health of Chinese women [1, 2]. The “Global strategy to accelerate the elimination of cervical cancer as a public health problem” was released at the WHO in November 2020 [3]. Elimination of cervical cancer by promoting the use of HPV vaccine is an important step.

HPV vaccines have been used globally for more than 10 years, and the efficacy of these vaccines, particularly in adolescent women, has been shown to be effective in reducing the incidence of HPV infection and CIN2+, according to international data [4]. Promoting the use of the HPV vaccine is a health challenge for China.

Characteristics of HPV Infection in Chinese Women

Among Chinese adult women, the rate of HR-HPV infection is 19.4% by opportunistic screening in hospitals [5], and is 15.0% by general population [6]; HR-HPV infection rate of women aged 15–19 years (who have had sexual experience) has reached 31% [7]. Among HR-HPV positive cases, 72% were infected with single HPV type, < 20% were infected with two HPV types, and < 8% were infected with three or more HPV types [8]. Age-specific
HPV prevalence peaked at two age groups in Chinese women (17–24 y and 40–44 y) [9]. These data show that HPV vaccination in China is a necessary prevention method for adolescents and can also be effective for adult women.

Clinical Trial Results for HPV Vaccines in China

From 2016, four kinds of HPV vaccines have been approved in China [10–12] (Table 1).

Immunogenicity of HPV Vaccines

In clinical trials in China, at 7 months after vaccination immunogenicity (96% to 100%) was observed after vaccinating women (ages 9-45y), regardless of which vaccine was used. After vaccination, antibody titer produced were 2 to 3 times higher in the younger age group than in older age group [10–12]. With the *E-coli* bv-HPV vaccine, immune response (IgG) was achieved after 2 or 3 doses in women aged 9-14y, but required 3 doses in women 18-26y. In women 9-14y, the neutralizing antibody level was higher after 2 doses than in women 18–26y after receiving 3 doses [13].

Efficacy of HPV Vaccines

Efficacy of the four vaccines against CIN2+ was 87.3–100%. Prevention of HPV-associated infection reached 96–97% at 12 months in clinical trials of the *E-coli*-bv-HPV, bv-HPV, and qv-HPV vaccines [10–12]. Clinical trials of the 9v-HPV vaccine are underway in China.

Safety of HPV Vaccines

Adverse events such as inoculation site side effects or systemic reactions may occur after vaccination from four types of HPV vaccine showed similar safety in clinical trials (Table 2). All four vaccines caused primarily local reactions, mostly presenting as transient mild reaction (> 10%) and moderate symptoms (1–10%). The most common local reactions were pain, erythema, and swelling. Systemic reactions included fever, headache, dizziness, muscle pain, arthralgia, and gastrointestinal symptoms (nausea, vomiting, or abdominal pain). No suspension of vaccination was required due to serious adverse events related to the vaccine; the rates of serious adverse events were comparable between the vaccine and placebo groups.

Challenges to HPV vaccination in China

Currently in China, vaccination is administered by the CDC, and the effects are observed by clinicians. The principle of voluntary and self-paid inoculation is used. The main reason is the high price of HPV vaccine in China, with the supply of vaccine insufficient, and the vaccine is not listed in the national immunization program. More education, research and development of HPV vaccines, expanded production, and promotion of the application of HPV vaccines in China are required.

Chinese Experts Consensus on the Clinical Application of HPV Vaccines

The Vaccine and Immunization Branch of Chinese Preventive Medical Association organized Chinese experts to discuss the etiology and related diseases of HPV and the

| Table 1 Four types HPV vaccines approved in China |
|-----------------------------------------------|
| Project | *E-coli*-bv-HPV vaccine | bv-HPV vaccine | qv-HPV vaccine | 9v-HPV vaccine |
|---------|-------------------------|----------------|----------------|----------------|
| Production enterprise | INNOVAXi, China | GSK, UK | MSD, USA | MSD, USA |
| Approved time | – | 2007 | 2006 | 2014 |
| Approved time in China | 2019.12 | 2016.7 | 2017.5 | 2018.4 |
| Prevention of HPV types | HPV 16/18 | HPV 16/18 | HPV 6/11/16/18 | HPV 6/11/16/18/31/33/45/52/58 |
| Prevent HPV infection-related diseases (approval by China) | Cervical cancer, CIN1, CIN2/3, AIS, HPV16/18 persistent infection | Cervical cancer, CIN1, CIN2/3, AIS | Cervical cancer, CIN1, CIN2/3, AIS | Cervical cancer, CIN1, CIN2/3, AIS, 9 HPV-associated subtypes of infection |
| Age of women vaccinated in China | 9–45 y | 9–45 y | 9–45 y | 16–26 y |
| Expression system | *E-coli* | Baculovirus | Saccharomyces cerevisiae | Saccharomyces cerevisiae |
| Vaccination schedule | 0 M, 1 M, 6 M (9–14 y: 0 M, 6 M) | 0 M, 1 M, 6 M | 0 M, 2 M, 6 M | 0 M, 2 M, 6 M |
application of HPV vaccines and reached a consensus and wrote the “Expert consensus on immunological prevention of Human Papillomavirus-related diseases” [14] in 2017.

To aid Chinese clinicians in understanding and guiding the use of HPV vaccine in Chinese women, especially in special populations, we have written the “Chinese experts consensus on the clinical application of HPV vaccine” [15]. In the consensus, recommended principles and precautions for vaccination of different populations are outlined, and challenges are addressed.

### Table 2 Adverse effects from four types of HPV vaccine

| Vaccine           | Very common ≥ 10% | Common 1%-10% | Accidental 0.1%-1% |
|-------------------|-------------------|---------------|--------------------|
|                   | Local Body        | Local Body    | Local Body         |
| E-coli-bv-HPV     | Pain, fever       | Induration redness, itching | Rash, Vomiting     |
| bv-HPV            | Pain, redness, swelling | Fatigue, myalgia, headache, fever (≥ 37 °C) | Rash               |
| qv-HPV            | Pain, redness, swelling | Induration and itching | Rash               |
| 9v-HPV            | Pain, redness, swelling | Induration and itching | Rash, Allergic reaction |

### Table 3 Recommended levels of HPV vaccination for general and special populations

| Crowd characteristics                                           | Recommended level |
|------------------------------------------------------------------|-------------------|
| General population                                               |                   |
| 9–26 y female                                                   | Priority recommended |
| 27–45 y female                                                  | Recommended       |
| Special population                                               |                   |
| HPV infection/ cytological abnormal                              | Recommended       |
| Pregnancy woman                                                 | Not recommended   |
| Lactation woman                                                 | Caution recommended |
| People with genetic susceptible population and high-risk population of cervical cancer | Priority recommended |
| People with immunodeficiency:                                   |                   |
| HIV infection                                                   | Recommended       |
| Autoimmune diseases:                                            | Recommended       |
| Systemic lupus erythematosus, Rheumatoid arthritis, Connective tissue disease, Sicca syndrome, Sjogren’s syndrome, Hashimoto’s thyroiditis | |
| Diabetes (types I and II)                                        | Recommended       |
| Patients with renal failure and Hemodialysis                    | Discuss with your clinician |
| Patients taking long-term immunosuppressive drugs after organ/bone marrow transplantation | Discuss with your clinician |

Recommendations for HPV vaccination are divided into five levels in China (Table 3):

### Recommendations of Vaccination

1. Recommended priority vaccination: for young women, because they potentially benefit the most, a preferred HPV vaccination strategy is promoted. (2) Recommended priority vaccination: preferential recommendation should also be taken for susceptible populations and those with a high-
risk of cervical cancer. (3) Recommended vaccination: recommended for adult women. (4) Recommended vaccination: women with immunodeficiency. (5) Vaccination not recommended: the vaccine is not recommended for pregnant women, who should be vaccinated 3 months after delivery. If pregnancy is discovered after initial vaccination dose, unfinished doses should be completed postpartum. (6) Caution is recommended: although the WHO proposed that vaccination can be done during lactation, it should be done cautiously, and vaccination should be delayed until after lactation.

Conclusion

In clinical studies, the HPV vaccine has shown efficacy, safety, and immunogenicity in Chinese women. We will continue to strengthen screening and push for HPV vaccination in the population. Much work is still required in the fight against cervical cancer. Through ongoing efforts, we can surely achieve the strategic goal of eliminating cervical cancer in China.

Acknowledgements Authors acknowledge Zhao C, Zhao Y, Li JR, Li MZ (Dept. OB/GYN of Peking University People’s Hospital); Xie X. (Dept. Gynecologic Oncology, Women’s Hospital, School of Medicine, Zhejiang University, Hangzhou, China); Liu JH. (Dept. Gynecologic Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, China); Qiao YL, Zhao FH. Chen W, Pan QJ. (National Cancer Center, National Center for Cancer Clinical Research, The Cancer Institute, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing, China ); Xia NS, Wu T, Zhang J (The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health, Xiamen University, Xiamen, Fujian, China); Ma D (Tongji Hospital of Huazhong University of Science and Technology); Kong BH (Qilu Hospital of Shandong University)

Funding Lihui Wei received Research funding grants, grants from supported by grants from the Chinese national High-tech R&D Program during the conduct of the study of E.coli bv-HPV vaccine, and non-financial support from Merck Sharp & Dohme R&D (China) and during the conduct of the study of qv-HPV vaccine.

Declaration

Conflict of interest The authors declared no potential conflicts of interest.

References

1. Data source: GLOBOCAN [R], 2018. https://gco.iarc.fr /today/online-analysis-multi-bars.
2. ICO HPV Information Centre. Human papillomavirus and related diseases report. China[R], 2019; 6–17.
3. WHO. Global strategy to accelerate the elimination of cervical cancer as a public health problem[EB/OL]. Geneva: World Health Organization; 2020.
4. Iarc. World cancer report: cancer research for cancer prevention[EB/OL]. 2020
5. Li K, Li Q, Song L, et al. The distribution and prevalence of human papillomavirus in women in mainland China[J]. Cancer. 2019;125(7):1030–7.
6. Bao HL, Jin C, Wang S, et al. Prevalence of cervicovaginal human papillomavirus infection and genotypes in the pre-vaccine era in China: A nationwide population-based study. J Infect 2021;82(4):75-83. doi:https://doi.org/10.1016/j.jinf.2021.02.017.
7. Wang R, Guo XL, Wisman GB, Schuuring E, Wang WF, Zeng ZY, Zhu H, Wu SW. Nationwide prevalence of human papillomavirus infection and viral genotype distribution in 37 cities in China. BMC Infect Dis. 2015;15:257.
8. Zhao FH, Lewkowitz AK, Hu SY, et al. Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China: a pooled analysis of 17 population-based studies[J]. Int J Cancer. 2012;131(12):2929–38.
9. Zeng Z, Yang H, Li Z, et al. Prevalence and Genotype Distribution of HPV Infection in China: analysis of 51,345 HPV genotyping results from China’s largest CAP certified laboratory[J]. J Cancer. 2016;7(9):1037–43.
10. Zhu FC, Hu SY, Hong Y, et al. Efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine in Chinese women aged 18–25 years: event-triggered analysis of a randomized controlled trial[J]. Cancer Med. 2017;6(1):12–25.
11. Wei L, Xie X, Liu J, et al. Efficacy of quadrivalent human papillomavirus vaccine against persistent infection and genital disease in Chinese women: a randomized, placebo-controlled trial with 78-month follow-up[J]. Vaccine. 2019;37(27):3617–24.
12. Qiao YL, Wu T, Li RC, et al. Efficacy, Safety, and Immunogenicity of an escherichia coli-produced bivalent human papillomavirus vaccine: An interim analysis of a randomized clinical trial[J]. J Natl Cancer Inst. 2020;112(2):145–53.
13. Hu YM, Guo M, Li CG, et al. Immunogenicity noninferiority study of 2 doses and 3 doses of an escherichia coli-produced HPV bivalent vaccine in girls vs 3 doses in young women. Sci China Life Sci. 2020;63(4):582–91.
14. Wang HQ, Zhao FH, Zhao Y, et al. Expert consensus on immunological prevention of Human papillomavirus-related diseases. Chin J Prev Med. 2019;53(8):761–804.
15. MaD, Wei LH, Xie X, Kong BH et al. Chinese expert consensus on clinical application of human papillomavirus vaccine. Chinese J Frontiers in Medical Science Electronic Edition, 2021; 13 (2):1–12. https://kns.cnki.net/kcms/detail/11.5882.R.20201012.1702.002.htm DOI:https://doi.org/10.12037/YXQY.2021.2-01

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.